Katherine A B Kellett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3737164/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Transcriptionally Active Amyloid Precursor Protein (APP) Intracellular Domain Is Preferentially Produced from the 695 Isoform of APP in a β-Secretase-dependent Pathway. Journal of Biological Chemistry, 2010, 285, 41443-41454.	1.6	175
2	A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis. Journal of Biological Chemistry, 2016, 291, 19235-19244.	1.6	151
3	Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers. Journal of Alzheimer's Disease, 2018, 63, 13-33.	1.2	111
4	Alkaline Phosphatase Is Increased in both Brain and Plasma in Alzheimer's Disease. Neurodegenerative Diseases, 2012, 9, 31-37.	0.8	71
5	Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer's disease: metabolic basis for dementia. Scientific Reports, 2016, 6, 27524.	1.6	68
6	Prion protein and Alzheimer disease. Prion, 2009, 3, 190-194.	0.9	66
7	BIN1 Is Decreased in Sporadic but Not Familial Alzheimer's Disease or in Aging. PLoS ONE, 2013, 8, e78806.	1.1	65
8	Prion Protein Interacts with BACE1 Protein and Differentially Regulates Its Activity toward Wild Type and Swedish Mutant Amyloid Precursor Protein. Journal of Biological Chemistry, 2011, 286, 33489-33500.	1.6	53
9	Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia?. Neurochemistry International, 2018, 118, 134-144.	1.9	39
10	Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers. Journal of Biological Chemistry, 2019, 294, 7085-7097.	1.6	38
11	Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid-Î ² Levels and Braak Stage. PLoS ONE, 2013, 8, e59554.	1.1	35
12	Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6770-6774.	1.0	28
13	Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells. Neurochemical Research, 2018, 43, 2179-2198.	1.6	27
14	3D hydrogel models of the neurovascular unit to investigate blood–brain barrier dysfunction. Neuronal Signaling, 2021, 5, NS20210027.	1.7	20
15	The Role of Tissue Non-specific Alkaline Phosphatase (TNAP) in Neurodegenerative Diseases: Alzheimer's Disease in the Focus. Sub-Cellular Biochemistry, 2015, 76, 363-374.	1.0	18
16	Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease. ACS Nano, 2021, 15, 7357-7369.	7.3	17
17	Discovery of Biphenylacetamide-Derived Inhibitors of BACE1 Using de Novo Structure-Based Molecular Design. Journal of Medicinal Chemistry, 2013, 56, 1843-1852.	2.9	16
18	Plasma metals as potential biomarkers in dementia: a case–control study in patients with sporadic Alzheimer's disease. BioMetals, 2018, 31, 267-276.	1.8	13

#	Article	IF	CITATIONS
19	Proteolysis of the low density lipoprotein receptor by bone morphogenetic protein-1 regulates cellular cholesterol uptake. Scientific Reports, 2019, 9, 11416.	1.6	13
20	Quantitative interaction proteomics reveals differences in the interactomes of amyloid precursor protein isoforms. Journal of Neurochemistry, 2019, 149, 399-412.	2.1	12
21	Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic Phenotype. PLoS ONE, 2016, 11, e0159119.	1.1	9